https://www.selleckchem.com/pr....oducts/sabutoclax.ht
2% (n = 94/292). The eradication rate according to an intention-to-treat analysis was 87.7% in the tailored group and 91.8% in the empirical group (P = 0.124); the respective rates were 94.4% and 97.9% by per-protocol analysis (P = 0.01. The frequency of adverse events was lower in the empirical group than the tailored group (35.1% vs. 52.7%, P 0.001). Total per capita medical costs were $406.50 and $503.50, respectively. Ten-day empirical BQT was more effective, safer, and less expensive than tailored therapy based on a CR te
Like
Comment
Share
